Is there a subset of patients with PSA ≥ 20 ng/ml who do well after conformal beam radiotherapy?

Radiation Oncology Investigations

Volumn 7, Issue 2, 1999, Pages 106-110

  Algan, Özer ^a,b   Pinover, Wayne H ^a   Hanlon, Alexandra L ^a   Al Saleem, T I ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

High risk; Prostate carcinoma; PSA 20; Radiotherapy; Treatment outcome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SCORING SYSTEM; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0032939120     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:2<106::AID-ROI6>3.0.CO;2-J     Document Type: Article

References (23)

1. Parker SL, Tongs T, Bolden S, Wingo PA. Cancer Statistics, 1997. Ca Cancer J Clin 1997;47:5-27.
2. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Follow-up. J Urol 1993;149:519-522.
3. Kuban DA, El-Mahdi AM, Schellhammer PF. Prostate specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-316.
4. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external beam radiotherapy alone: Serum prostate-specific antigen- driven outcome analysis. J Clin Oncol 1995;13:464-469.
5. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
6. Pisansky TM, Cha SS, Earle JD, Durr DE, Kozelsky TF, Wieand HS, Oesterling JE. Prostate specific antigen as pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-2166.
7. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10: 1208-1217.
8. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
9. Zeitman AL, Coen JJ, Shipley WU, Willett CG, Efrid JT. Radical radiation therapy in the management of prostate adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-645.
10. Algan O, Hanks GE, Shaer AH. Localization of the prostatic apex for radiation treatment planning. Int J Rad Oncol Biol Phys 1995;33:925-930.
11. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiol Oncol Biol Phys 1997;37:1035-1041.
12. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc.; 1980.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-481.
14. Lawless JE. Statistical models and methods for lifetime data. New York: John Wiley & Sons, Inc.; 1982.
15. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, Brabbins DS, Hollander J, Chen PY, Martinez AA. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiol Oncol Biol Phys 1996; 36:565-571.
16. Sandler HM, McLaughlin PW, Kish KE, Lichter AS. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. Abst #1, 37th Annual ASTRO meeting, 1995.
17. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma, Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-1380.
18. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J Urol 1995;154: 456-459.
19. Pilepich MV, Krall JM, Sause WT, Johnson RJ, Russ HH, Hanks GE, Perez CA, Zinninger M, Martz KL. Prognostic factors in carcinoma of the prostate: Analysis of RTOG 75-06. Int J Radiol Oncol Biol Phys 1987; 13:339-349.
20. Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-of-failure analysis of patients with high pretreatment PSA treated by radiation therapy: The need for improved systemic and loco- regional treatment. J Clin Oncol 1996;14:1093-1097.
21. Hanks GE, Hanlon AL, Schultheiss TE, Freedman GM, Hunt M, Pinover WH, Movsas B. Conformal external beam treatment of prostate cancer. Urology 1997;50: 87-92.
22. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New England J Med 1997; 337:295-300.
23. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997;15:1013-1021.